Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort

Clas Göran Af Björkesten, Tuire Ilus, Taru Hallinen, Erkki Soini, Anja Eberl, Kalle Hakala, Mikko Heikura, Airi Jussila, Ritva Koskela, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Urpo Nieminen, Heikki Nuutinen, Markku Heikkinen, Ulla Maija Suhonen, Jyrki Tillonen, Karri Utriainen, Ilkka Vihriälä, Christina WennerströmAndras Borsi, Riikka Nissinen, Minni R. Koivunen, Taina Sipponen

Research output: Contribution to journalArticleScientificpeer-review

1 Citation (Scopus)


Objective Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn's disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn's disease patients treated with ustekinumab. Methods The study was conducted in 17 Finnish hospitals and included adult Crohn's disease patients who received an initial intravenous dose of ustekinumab during 2017-2018. Disease activity data were collected at baseline, 16 weeks, and 1 year from health records. Results The study included 155 patients. The disease was stricturing or penetrating in 69 and 59% had prior Crohn's disease-related surgeries, and 97% had a treatment history of at least one biologic agent. Of 93 patients with ≥1 year of follow-up, 77 (83%) were still on ustekinumab at 1 year. In patients with data available, from baseline to the 1-year follow-up the simple endoscopic score for Crohn's disease (SES-CD) decreased from 10 to 3 (P = 0.033), C-reactive protein from 7 to 5 mg/L, (P < 0.001) and faecal calprotectin from 776 to 305 μg/g (P < 0.001). Conclusions Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity.

Original languageEnglish
Pages (from-to)1507-1513
Number of pages7
Publication statusPublished - 2020
Publication typeA1 Journal article-refereed


  • biologics
  • biomarkers
  • calprotectin
  • Crohn's disease
  • endoscopic healing
  • inflammatory bowel disease
  • simple endoscopic score for Crohn's disease
  • ustekinumab

Publication forum classification

  • Publication forum level 1

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort'. Together they form a unique fingerprint.

Cite this